Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
sabirnetug · 2 trials · 1 indication
iADRS is a validated composite of cognition and function made up of Alzheimer's Disease Assessment Scale - Cognitive Subscale 13-item (ADAS-Cog13) and the Alzheimer's Disease Cooperative Study - instrumental Activities of Daily Living scale (ADCS-iADL). ADAS-Cog13 is a rater-administered instrument consisting of 13 items assessing cognitive function areas most typically impaired in AD. ADAS-Cog13 scores range from 0 to 85, with higher scores indicating a greater deficit of global cognition. The ADCS-iADL is a subset of the 23-item ADCS-ADL (items 6a and 7 to 23). The iADLs are more complex skills required to successfully live independently. iADL-items score ranges from 0 to 59 (lower scores indicating greater impairment). The iADRS is calculated as a linear combination of total scores from the ADAS-Cog13 and ADCS-iADL. The iADRS score ranges from 0 to 144 with lower scores indicating worse performance.
Cmax (Maximum concentration, determined directly from individual concentration-time data)
Tmax (Time of the maximum concentration)
λz (The observed terminal rate constant; estimated by linear regression through at least three data points in the terminal phase of the log concentration-time profile)
T1/2 (The observed terminal half-life)
AUC168h (Area under the concentration-time curve during a one-week dosing interval)
AUClast (Area under the concentration-time curve from time zero to the time of the last quantifiable concentration; calculated using the linear trapezoidal rule)
AUCinf (Area under the concentration-time curve from time zero extrapolated to infinity)
AUCExtrap (%)(The percentage of AUCinf based on extrapolation)
Clast (The last quantifiable concentration determined directly from individual concentration-time data)
Tlast (Time of the last quantifiable concentration)
| Arm | Type | Description |
|---|---|---|
| Double-blind Treatment (DBT) Period: sabirnetug 35 mg/kg | EXPERIMENTAL | Participants will receive sabirnetug, 35 milligrams per kilogram (mg/kg), Q4W as intravenous (IV) infusion during the DBT period. |
| DBT Period: sabirnetug 50 mg/kg | EXPERIMENTAL | Participants will receive sabirnetug, 35 mg/kg, for the first two doses, followed by sabirnetug, 50 mg/kg, Q4W as an IV infusion during the DBT period. |
| DBT Period: Placebo | PLACEBO_COMPARATOR | Participants will receive sabirnetug matching placebo, Q4W as an IV infusion during the DBT period. |
| Open-Label Extension (OLE) Period: sabirnetug 35 mg/kg | EXPERIMENTAL | Participants will receive sabirnetug, 35 mg/kg, Q4W as an IV infusion during the OLE period. |
| Arm 1 | EXPERIMENTAL | 12 participants receive sabirnetug by intravenous infusion |
| Arm 2 | EXPERIMENTAL | 16 participants receive sabirnetug + rHuPH20 by subcutaneous injection |
| Name | Type | Description |
|---|---|---|
| sabirnetug | DRUG | Intravenous sabirnetug |
| Placebo | DRUG | Intravenous Placebo |
| sabirnetug (ACU193) | DRUG | sabirnetug by intravenous infusion |
| Sabirnetug + rHuPH20 | COMBINATION_PRODUCT | sabirnetug + rHuPH20 by subcutaneous injection |
Inclusion Criteria: * Body weight of at least 30 kilograms (kg) (66 pounds \[lbs\]) and no more than 160 kg (352 lbs) at Screening * Must consent to apolipoprotein E4 (APOE4) genotype status assessment * Must meet all of the following criteria 1. National Institute on Aging-Alzheimer's Associati...
Top 20 of 24 competitors
Sabirnetug is an investigational small molecule being developed for the treatment of Alzheimer Disease. It is currently in Phase 2 clinical development and has not been approved by the FDA. The drug is being studied in patients with early Alzheimer's disease.
Sabirnetug is being developed by Acumen Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ABOS. The company is conducting clinical trials to evaluate the drug's safety and efficacy in Alzheimer's disease.
Sabirnetug is currently in Phase 2 clinical development for Alzheimer Disease. It has received Fast Track designation from the FDA, which is intended to expedite the development and review of drugs for serious conditions. The drug remains investigational and is not yet approved.
Sabirnetug is being evaluated in two clinical trials. The Phase 2 trial NCT06335173, named ALTITUDE-AD, is an active, placebo-controlled study in 542 participants with early Alzheimer's disease across the US, Canada, Germany, Spain, and the UK. A Phase 1 trial NCT06511570, comparing intravenous and subcutaneous formulations, has been completed.
Sabirnetug is not FDA approved. It is an investigational drug currently in Phase 2 clinical trials for Alzheimer Disease. The FDA has granted it Fast Track designation, which facilitates development, but the drug has not yet received marketing approval.